STOCK TITAN

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

Amgen (NASDAQ:AMGN) has announced its quarterly dividend for the first quarter of 2025. The company's Board of Directors has declared a dividend of $2.38 per share. Shareholders who are recorded as stockholders by the close of business on February 14, 2025, will receive the dividend payment on March 7, 2025.

Amgen (NASDAQ:AMGN) ha annunciato il suo dividendo trimestrale per il primo trimestre del 2025. Il Consiglio di Amministrazione della società ha dichiarato un dividendo di $2,38 per azione. Gli azionisti che risulteranno registrati come tali entro la chiusura delle operazioni del 14 febbraio 2025 riceveranno il pagamento del dividendo il 7 marzo 2025.

Amgen (NASDAQ:AMGN) ha anunciado su dividendo trimestral para el primer trimestre de 2025. La Junta Directiva de la empresa ha declarado un dividendo de $2,38 por acción. Los accionistas que estén registrados como tales al cierre de la jornada del 14 de febrero de 2025 recibirán el pago del dividendo el 7 de marzo de 2025.

암겐 (NASDAQ:AMGN)은 2025년 첫 분기의 분기 배당금을 발표했습니다. 회사의 이사회는 주당 $2.38의 배당금을 선언했습니다. 2025년 2월 14일 영업 종료 시 주주로 기록된 주주들은 2025년 3월 7일에 배당금 지급을 받게 됩니다.

Amgen (NASDAQ:AMGN) a annoncé son dividende trimestriel pour le premier trimestre de 2025. Le conseil d'administration de l'entreprise a déclaré un dividende de 2,38 $ par action. Les actionnaires enregistrés comme tels à la clôture des affaires le 14 février 2025 recevront le paiement du dividende le 7 mars 2025.

Amgen (NASDAQ:AMGN) hat seine vierteljährliche Dividende für das erste Quartal 2025 bekannt gegeben. Der Vorstand des Unternehmens hat eine Dividende von 2,38 $ pro Aktie erklärt. Aktionäre, die bis zum Geschäftsschluss am 14. Februar 2025 als Aktionäre registriert sind, erhalten die Dividendenzahlung am 7. März 2025.

Positive
  • Continued commitment to shareholder returns through dividend payments
  • Maintains $2.38 per share quarterly dividend level
Negative
  • None.

THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.  

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. 

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.  

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks 
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)  

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html

SOURCE Amgen

FAQ

What is Amgen's (AMGN) dividend amount for Q1 2025?

Amgen's dividend for the first quarter of 2025 is $2.38 per share.

When will Amgen (AMGN) pay its Q1 2025 dividend?

Amgen will pay its Q1 2025 dividend on March 7, 2025.

What is the record date for Amgen's (AMGN) Q1 2025 dividend?

The record date for Amgen's Q1 2025 dividend is February 14, 2025.

How much will Amgen (AMGN) shareholders receive per share in Q1 2025?

Amgen shareholders will receive $2.38 per share for the first quarter of 2025.

Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Stock Data

143.27B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS